Health Care Roundup: Market Talk

Dow Jones01:20

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0538 ET - A potential acquisition by Sanofi of U.S. drugmaker Insmed looks doable, digestible and consistent with what the French company's new CEO is aiming for, analysts at Jefferies say in a research note. Bloomberg reported Thursday that Sanofi is considering an acquisition of Insmed. Sanofi declined to comment when contacted by Dow Jones Newswires, and Insmed didn't respond to a request for comment. While a potential Insmed acquisition would rank among the largest biopharma deals in recent years, it isn't out of reach for Sanofi, Jefferies says. Sanofi can probably spend more than 25 billion euros on an acquisition, and Insmed would cost it around 31 billion euros with the typical deal premium, the analysts say. A deal would improve Sanofi's trajectory beyond the patent expiration of blockbuster drug Dupixent, they add. Sanofi shares rise 1.7%. (adria.calatayud@wsj.com)

0131 ET - The market reaction to Novartis's medium-term targets seems overdone, with sales guidance as expected and executives pointing to AI gains that look set to boost profitability, RBC Capital Markets analysts say in a research note. "The +5% mid-term sales growth was in line with our expectations, and hopes for higher were unrealistic, in our view," the analysts say. Moreover, executives at the Swiss drugmaker did a good job explaining the prospects for growth drivers such as its key approved medicines Rhapsido and Kisqali, as well as drug candidates ianalumab and abelacimab, the analysts add. Novartis also detailed how AI is set to help it reduce costs and accelerate workflows, which could allow it to hit its 2029 profitability goal early, according to RBC. Novartis shares closed 3.2% lower at 127.24 Swiss francs. (adria.calatayud@wsj.com)

0044 ET - Bumrungrad Hospital's earnings recovery is likely to be driven by pent-up demand once Middle East tensions ease, CGS International's Kasem Prunratanamala says in a research report. The hospital's defensive earnings profile positions it well amid heightened global uncertainties, while a gradual easing of Mideast tensions should support a rebound in international patient traffic, the analyst says. Its recent share-price correction offers attractive accumulation opportunity for investors with a medium- to long-term investment horizon. The brokerage maintains the stock's add rating, but raises the target price to 242.00 baht from 212.00 baht based on a higher target multiple that partly reflects the Thai hospital's earnings resilience. Shares are 1.4% lower at 178.50 baht. (ronnie.harui@wsj.com)

1441 ET - Anthropic shares trade well above their IPO price, but the rest of the market is selling off with weakness from the neocloud sector to health insurance. UnitedHealth Group slides 4.6% after plunging 10% Wednesday following the government pledge to crack down on Medicare Advantage fraud earlier this week and lawmakers renewed a call for Medicare for All. Centene, Cigna and Elevance Health are all lower as well. Neoclouds CoreWeave, Nebius and IREN are all down over 4% as investors continue to worry about financing the AI infrastructure buildout. DJIA is off 1.7%, S&P 500 drops 1.4% and the Nasdaq slides 1.6%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment